A phase 2 trial in pancreatic cancer, run by National Cancer Centre, Singapore, now recruiting.
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT05929885 by National Cancer Centre, Singapore, with a registry enrolment figure of 50 participants, started 2023-08-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: Low Dose OXIRI (LD-OXIRI). Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR).; Clinical Benefit Rate (CBR).; The Grade 3-5 Toxicity Rate.. Pancreatic eligibility wording from the registry: "Histopathological diagnosis of pancreatic cancer". Sites: Singapore. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.